QRxPharma’s Dual-Opioid Therapy MoxDuo Will Face FDA Cmte. Scrutiny
This article was originally published in The Pink Sheet Daily
FDA told the company there is no precedent for reviewing a combination product that contains two drugs from the same class. The company’s NDA resubmission for the morphine/oxycodone immediate-release product will include oxygen saturation data from a study originally conducted for European regulators.
You may also be interested in...
By the third year of continuing medical education efforts, FDA expects 60% of those who wrote a prescription for a long-acting/extended-release opioid in 2011 to receive training.
Actavis aims to replace its Kadian pain franchise through a deal with QRxPharma for a fixed-dose combination of morphine and oxycodone.
Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.